NCCN Guidelines Insights: Prostate Cancer, Version 1.2021-Reference-Cited by-同舟云学术

NCCN Guidelines Insights: Prostate Cancer, Version 1.2021

Published:2021-02 Issue:2 Volume:19 Page:134-143
ISSN:1540-1405
Container-title:Journal of the National Comprehensive Cancer Network
language:
Short-container-title:

Author:

Schaeffer Edward¹,Srinivas Sandy²,Antonarakis Emmanuel S.³,Armstrong Andrew J.⁴,Bekelman Justin E.⁵,Cheng Heather⁶,D’Amico Anthony Victor⁷,Davis Brian J.⁸,Desai Neil⁹,Dorff Tanya¹⁰,Eastham James A.¹¹,Farrington Thomas A.¹²,Gao Xin⁷,Horwitz Eric Mark¹³,Ippolito Joseph E.¹⁴,Kuettel Michael R.¹⁵,Lang Joshua M.¹⁶,McKay Rana¹⁷,McKenney Jesse¹⁸,Netto George¹⁹,Penson David F.²⁰,Pow-Sang Julio M.²¹,Reiter Robert²²,Richey Sylvia²³,Roach, III Mack²⁴,Rosenfeld Stan²⁵,Shabsigh Ahmad²⁶,Spratt Daniel E.²⁷,Teply Benjamin A.²⁸,Tward Jonathan²⁹,Shead Dorothy A.³⁰,Freedman-Cass Deborah A.³⁰

Affiliation:

1. 1Robert H. Lurie Comprehensive Cancer Center of Northwestern University;

2. 2Stanford Cancer Institute;

3. 3The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins;

4. 4Duke Cancer Institute;

5. 5Abramson Cancer Center at the University of Pennsylvania;

6. 6Fred Hutchinson Cancer Research Center/Seattle Cancer Care Alliance;

7. 7Dana-Farber/Brigham and Women’s Cancer Center | Massachusetts General Hospital Cancer Center;

8. 8Mayo Clinic Cancer Center;

9. 9UT Southwestern Simmons Comprehensive Cancer Center;

10. 10City of Hope National Cancer Center;

11. 11Memorial Sloan Kettering Cancer Center;

12. 12Prostate Health Education Network (PHEN);

13. 13Fox Chase Cancer Center;

14. 14Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine;

15. 15Roswell Park Comprehensive Cancer Center;

16. 16University of Wisconsin Carbone Cancer Center;

17. 17UC San Diego Moores Cancer Center;

18. 18Case Comprehensive Cancer Center/University Hospitals Seidman Cancer Center and Cleveland Clinic Taussig Cancer Institute;

19. 19O'Neal Comprehensive Cancer Center at UAB;

20. 20Vanderbilt-Ingram Cancer Center;

21. 21Moffitt Cancer Center;

22. 22UCLA Jonsson Comprehensive Cancer Center;

23. 23St. Jude Children’s Research Hospital/The University of Tennessee Health Science Center;

24. 24UCSF Helen Diller Family Comprehensive Cancer Center;

25. 25University of California San Francisco Patient Services Committee Chair;

26. 26The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute;

27. 27University of Michigan Rogel Cancer Center;

28. 28Fred & Pamela Buffett Cancer Center;

29. 29Huntsman Cancer Institute at the University of Utah; and

30. 30National Comprehensive Cancer Network.

Abstract

The NCCN Guidelines for Prostate Cancer address staging and risk assessment after a prostate cancer diagnosis and include management options for localized, regional, and metastatic disease. Recommendations for disease monitoring and treatment of recurrent disease are also included. The NCCN Prostate Cancer Panel meets annually to reevaluate and update their recommendations based on new clinical data and input from within NCCN Member Institutions and from external entities. This article summarizes the panel’s discussions for the 2021 update of the guidelines with regard to systemic therapy for metastatic castration-resistant prostate cancer.

Publisher

Harborside Press, LLC

Subject

Oncology

Link

https://jnccn.org/downloadpdf/journals/jnccn/19/2/article-p134.xml

Cited by 299 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Active surveillance of low-grade prostate cancer using the SurACaP Criteria: A multi-institutional series with a median follow-up of 10 years;The French Journal of Urology;2024-03

2. The Impact of Positron Emission Tomography Imaging and Tumor Molecular Profiling on Risk Stratification, Treatment Choice, and Oncological Outcomes of Patients with Primary or Relapsed Prostate Cancer: An International Collaborative Review of the Existing Literature;European Urology Oncology;2024-02

3. Pembrolizumab for metastatic castration-resistant prostate cancer: trials and tribulations;Expert Opinion on Biological Therapy;2024-01-29

4. Grade group 4 prostate cancer without intraductal carcinoma on biopsy is more likely to be downgraded on prostatectomy than with intraductal carcinoma;Virchows Archiv;2024-01-25

5. Improving the identification of high-risk non-metastatic castration-resistant prostate cancer patients in clinical practice;Frontiers in Oncology;2024-01-23